#lifesciences Tag

26 Oct

Posted at 10:26h in Technology

Editorial Notice: This comparison was contributed by Matrix One, the maker of Matrix Quality. Rankings and product descriptions reflect the contributor's opinion and vendor-provided information and are not an endorsement by MedicalResearch.com or Eminent Domains Inc. Pricing, features, and implementation times may change; confirm details and regulatory obligations directly with vendors and your quality and regulatory teams.

Eight eQMS platforms are worth comparing for life science and medical device companies in 2026: Matrix Quality, Scilife, ZenQMS, Dot Compliance, Cognidox, qmsWrapper, Isolocity and Qualityze. Matrix Quality is the contributor's top pick because, according to the company, it comes with vendor-supplied validation documentation for Part 11, Annex 11, ISO 13485 and GxP, goes live in 2 to 6 weeks, publishes its pricing from €10,000 a year, and is used by 500 life science companies worldwide.

Matrix Quality is an electronic quality management system for medical device and life science companies that have outgrown paper, Word, Excel and SharePoint or Google Workspace. It is aimed at growing teams of 20 to 1,000 people who need an audit-ready QMS without an enterprise price or an enterprise rollout.

12 Oct

Posted at 17:38h in Laboratories

Editorial Notice: This article is general information, not legal, regulatory, or business advice. Consulting firms mentioned or linked here are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Confirm services, qualifications, and terms directly with any provider you consider.

Picture a project lead in Raleigh's Research Triangle on a Monday morning: a facility qualification deadline is closing in, two key validation specialists just resigned and the audit calendar is already full. Everyone is working hard, yet the plan keeps slipping. Moments like this are common in life sciences, where regulation, technology and timelines all move at once. Bringing in outside help is not an admission of failure, but knowing when to do it is a real skill. Here are five signs it may be time, along with practical ways to evaluate your options. This is general information, not legal, regulatory or business advice, so check specifics with qualified professionals. [caption id="attachment_76551" align="aligncenter" width="500"]Life Sciences companies pexels Pexels image[/caption]

25 Mar

Posted at 13:18h in Insurance
[caption id="attachment_72926" align="aligncenter" width="500"]Product Liability Insurance Freepix[/caption] Innovation is at the heart of the life sciences industry. Whether developing new medicines, producing advanced medical devices, or driving progress in biotechnology and digital health, organisations in this space play a critical role in improving and extending lives.

However, the impact of these products also means the risks are significant. If a product fails—due to a defect, contamination, incorrect instructions or a systems error—the consequences can be severe. Businesses may face claims involving patient injury, financial losses, regulatory intervention and lasting reputational harm.

For this reason, product liability life science insurance is a key consideration for companies operating across the life sciences sector. Below, we explore what it covers, who should consider it, and the wider risk landscape.

Understanding Product Liability in Life Sciences

Product liability insurance is designed to protect businesses when a product they manufacture, supply or distribute causes harm or damage.

Within life sciences, the nature of these risks is often more complex than in other sectors. Potential causes of claims include:

  • Flaws in product design
  • Errors during manufacturing
  • Insufficient instructions or safety warnings
  • Software or system failures in medical technologies
  • Contamination during production or storage
  • Weaknesses in quality assurance processes

Given the strict regulatory environment in the UK and beyond, any failure can quickly escalate. Claims may involve substantial compensation payments, legal costs and scrutiny from regulatory authorities.